Introduction
Preclinical and clinical biomarkers are key factors in shortening the timeline and increasing the success rate of the drug development process and are an area of intense investigation. [1] [2] [3] The term 'biomarker' is often used indiscriminately to describe any gene or protein expression change, but has been strictly defined by the NIH Biomarkers Definitions Working Group as 'a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacologic responses to a therapeutic intervention'. 4 Several excellent reports have examined the use and qualification of clinical biomarkers. [5] [6] [7] In preclinical drug development, biomarkers can be used to monitor disease models, pharmacodynamics, pharmacoefficacy and toxicology. 1 Although many disease-specific end points exist for measuring pharmacoefficacy, their use is often constrained by the cost and time required to perform the assay (for example, behavior) and the modest magnitude of change shown with disease (limited dynamic gain). Molecular biomarkers offer the potential to speed initial preclinical testing of drugs through high-throughput, high-gain measurements of pharmacoefficacy. Although biomarkers are not intended to totally replace traditional measures of pharmacoefficacy, the aim of integrating biomarkers into drug development is to provide a rapid and reliable initial screen of efficacy, which can be followed at later stages of drug development by efficient use of more time-consuming and expensive traditional measures (for example, behavioral and physiological assays) ( Figure 1 ). However, only a few reports have described the validation process for preclinical drug development biomarkers, and these have not focused on in vivo disease models. [8] [9] [10] The purpose of preclinical biomarkers is to provide quantitative data for rational decision-making in drug development, so biomarkers must be fully validated before use. We propose a linear process for the development of preclinical biomarkers that may serve as an example for other efforts and aid preclinical drug development.
We used diabetic retinopathy (DR) as a case study to show application of the proposed biomarker development process. Loss or impairment of vision due to DR is one of the most profound complications of diabetes, and ablative laser surgery for advanced disease continues to be the standard of care for DR. As members of a translational drug development center, we test potential DR pharmacotherapeutics in preclinical models and determine if clinical development is warranted. Pharmacological treatments have shown promise in prevention and/or reversal of DR, but currently there are no Food and Drug Administration-approved pharmacotherapeutic agents aside from glycemic control through insulin replacement 11 and blood pressure control. 12 Therefore, continued research into potential DR treatments is vitally needed.
Similar to many other disorders, DR drug development is currently hampered by inadequate clinical and preclinical biomarkers. 13 Recent research has identified several proteins in the vitreous of patients with DR 14, 15 and new visual function tests 16 that could potentially serve as clinical diagnostic biomarkers and surrogate end points in clinical trials. For preclinical studies in rodents, visual testing is problematic and therefore drug development relies on assays such as retinal vascular permeability and neuronal apoptosis. These assays have known relevance to DR disease processes but are labor intensive or have limited effect sizes, and require large sample numbers for adequate statistical power. In these instances, implementation of tests using molecular biomarkers can aid drug development as an initial high-throughput assessment of therapeutic interventions. Numerous changes in gene and protein expression have been reported in DR animal models 14, 15, [17] [18] [19] that share important commonalities with clinical features of human DR, 14, 20, 21 but no previous reports have developed these changes into validated biomarkers for use in preclinical drug development studies.
The aim of this report was to develop and show a process for biomarker validation using a preclinical model of DR as a case study. Specifically, a gene expression biomarker panel was used to monitor pathophysiology and pharmacoefficacy using a rigorous validation process in a DR preclinical disease model as shown in Figure 1 . The process begins with
Step 1, determining the pathological sequence of events to ensure that the biomarker development is conducted at the appropriate stage of disease. The time course of pathophysiology was determined from our previous studies. 19, 22, 23 In Step 2, potential biomarkers were identified from data in our genome-wide gene expression database. 19 The reproducibility of gene expression changes across multiple independent animal experiments was then assessed to determine the most consistent changes in Step 3. Those genes with statistically significant changes across all animal experiments were retained, whereas genes that failed to consistently reach statistical significance were eliminated as components of the biomarker panel. In Step 4, the most compact panel of genes that could serve as accurate
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Step Figure 1 Biomarker development and implementation process. All gene expression changes are often mistakenly assumed to be biomarkers. To be considered biomarkers, however, gene expression changes require a number of validation steps. These include showing a high degree of reproducibility in independent experiments, technical reproducibility, classification ability and if possible response to a known therapeutic agent. An example of each of these steps is presented in this study. With completion of development, the biomarker panel can be used in preclinical drug development decision-making. In tests of potential new therapeutics, the biomarker panel is used to measure pharmacoefficacy in a rapid and reliable manner. Effective treatments will result in the biomarker panel returning a control classification and are confirmed by traditional physiological or behavioral end points. Ineffective treatments (or doses, formulations and so on) will result in a disease classification and no need for further tests. Therapeutic compounds that fail are either eliminated or are optimized before retesting.
indicators of health or disease was determined. This was established using multiple independent animal experiments as Training and Test sets. Finally, in Step 5, the ability of the biomarker panel to gauge pharmacotherapeutic efficacy was then tested using insulin, the established standard of care treatment agent to prevent DR. Testing of the biomarker panel against a known therapeutic is recommended but is not possible for those conditions with no known effective treatments.
After completion of biomarker development, a biomarker panel can be integrated into the preclinical drug development process to rapidly assess therapeutics, including optimization of doses, formulations and delivery methods. Efficacious treatments, as judged by the ability to induce a 'control' biomarker classification in disease model samples, would then advance to traditional end-point evaluation, whereas negative results would indicate an ineffective drug, dose, formulation or delivery method. The benefit to drug development is exemplified by dose-response studies where biomarker assessment of pharmacoefficacy would allow rapid identification of effective doses for more time-consuming and expensive physiological or behavioral analyses.
The data presented here describe the steps in development of a biomarker panel for use in preclinical drug development, using the example of DR. This particular biomarker panel is intended solely for preclinical use. The biomarker development process is designed to produce a biomarker panel that meets the standards of a 'probable valid biomarker' and could be used in preclinical evaluations of pharmacoefficacy to speed drug development. 24 The steps outlined here for developing preclinical biomarkers are intended to be applicable to any disease process and may use any of the classification algorithm approaches available.
Materials and methods

Animal treatments
All rats were maintained by the Penn State JDRF Animal Models Core in accordance with the Institutional Animal Care and Use Committee guidelines under specific pathogen-free conditions and monitored by quarterly sentinel testing. Sprague-Dawley male rats (Charles River Laboratories, Wilmington, MA, USA) arrived at 100-125 g. After 1 week and following an overnight fast, diabetes was induced by intraperitoneal injection of 65 mg kg À1 streptozotocin (STZ; Sigma-Aldrich, St Louis, MO, USA) in 10 mM sodium citrate (pH 4.5) vehicle. Control rats were injected with an equal dose of vehicle only. Rats had free access to food and water, and were on a 12 h light/dark cycle. Blood glucose level and body weight were measured 6 days after STZ or vehicle injection, and biweekly throughout the experiment. Only rats with blood glucose levels 4250 mg per 100 ml at the time of the original test were included in the diabetic groups (Table 1, Online Appendix). No exogenous insulin was delivered in animal Experiments 1-7. For animals in Experiment 8, the insulin treatment group received one 26 mg subcutaneous pellet (LinShin Canada, Scarborough, Canada) delivered by trocar 2, 4 or 6 weeks after STZ injection. An additional 26 mg implant was introduced when body weight exceeded 300 g or when midday nonfasting blood glucose exceeded 250 mg per 100 ml. At the time of retinal harvest, rats were given a lethal dose of pentobarbital, 100 mg kg À1 (Ovation Pharmaceuticals, Deerfield, IL, USA) by intraperitoneal injection. Retinas were excised and either quickly frozen in liquid nitrogen for RNA isolation or processed immediately for caspase activity as described below.
RNA isolation
Total RNA was isolated with Tri-Reagent/BCP (Molecular Research Center, Cincinnati, OH, USA) following standard methods. 19 Quality and quantity was assessed using the RNA 6000 Nano LabChip with an Agilent 2100 Expert Bioanalyzer (Agilent, Palo Alto, CA, USA) and NanoDrop ND100 (NanoDrop, Wilmington, DE, USA).
Quantitative RT-PCR
Quantitative PCR analysis was performed as described previously, 19, 25 using the 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA), 384-well optical plates and Assay-On-Demand (Applied Biosystems) gene specific primers and probes. SDS 2.2.2 software (Applied Biosystems) and the 2
ÀDDCt analysis method were used to quantitate relative amounts of product using b-actin as an endogenous control. 26 b-Actin levels were determined to be unchanged in an absolute quantitation experiment (data not shown). For a full listing of primer/probe sets see Supplementary Table S1 . The full complement of the qPCR gene expression data is contained in Supplementary Data File 1.
Bioinformatic and statistical methods
For statistical analysis of qPCR data, standard parametric t-tests (ao0.05, one-tailed) were used. Each animal experiment was treated independently because the animals were generated and harvested separately. Support vector machine (SVM), gene selection and heat-map analyses were performed with GeneSpring 7.3 (Agilent). The SVM algorithm used either Gaussian or polynomial kernel functions with or without scaling factors as detailed in the Results section. Predictive accuracy was computed by dividing the correct number of predictions by the total number of predictions. Table 1 summarizes all animal data from this study. At harvest, diabetic rats were hyperglycemic and underweight compared with controls as with previous assessments. 19, [27] [28] [29] Treatment with subcutaneous slow-release insulin pellets for the second half of the diabetic period reduced blood glucose levels, and diabetic animals receiving insulin weighed more than untreated diabetic animals. These data and the methods described are representative of experiments performed by the Penn State JDRF Diabetic Retinopathy Center Animal Models Core since 2003. 19, [27] [28] [29] Step 1: Defining pathological dysfunction The first step of the process links the biomarker panel with pathophysiological end points relevant to the disease model. We previously showed the time course of retinal tissue pathology (vascular permeability and apoptosis) in the STZ rat model of diabetes (Table 2 ). In an initial report, 22 we observed a 62% increase in retinal vascular permeability after 3 months of diabetes. We then confirmed both the increase in permeability after 3 months of diabetes and the absence of an increase in permeability after 1 month of diabetes (Table 2) . 19 We have also reported increased retinal caspase-3 activity after 3 months of diabetes, but not after 1 month of diabetes, in the STZ rat model 19 and documented that nonvascular cells in the retinal ganglion cell layer are undergoing apoptosis. 30, 31 Thus, the functional alterations make the 3-month time point the focus of the present biomarker development study.
Results
Animal data
Step 2: Biomarker target identification for biomarker development The second step of the process identifies individual biomarker targets as potential components of the biomarker panel. Using a microarray database of retinal gene expression changes in the STZ-diabetic rat model at 1 and 3 months of hyperglycemia, 19 we selected 45 gene targets for development of a biomarker panel, (Step 2, Figure 1 ; genes listed in Table 3 ). This work has been described in a previous report 19 and highlights the utility of generating genome-wide gene expression profiles. These profiles are not only informative of the pathobiology of disease but can be subsequently mined for biomarker development studies such as this. On the basis of literature searches and the Ingenuity Pathway Analysis System database, the 45 biomarker targets have possible roles in the inflammation, neurodegeneration and blood-retinal barrier dysfunction that occur in DR pathophysiology.
Step 3: Confirmation of gene expression changes by an orthogonal technique in multiple independent animal experiments The third step of the process queries the reproducibility of changes in expression of the individual targets across multiple experiments (Step 3, Figure 1 ). In this analysis, the 45 specific transcripts identified in Step 2 were assessed across three experiments of control and diabetic animals (Experiments 1-3, Table 1 ) and in these three experiments, 25 genes (Table 3 ) were found to be consistently altered in a statistically significant manner (see Figure 2 for the expression results of these 25 genes in animal Experiment 1). Twenty of the transcripts were not consistently changed in diabetic groups; that is, they did not reach statistical significance in each independent experiment. Although many of these 20 genes were significantly altered in some or most of the experiments, they were eliminated from the potential biomarker panel to provide the most consistent and informative panel possible.
To assess the time of onset of these gene expression changes, we examined the 25 consistently regulated genes at 2 weeks and 1 month of diabetes (Experiments 1-3) . Only a few gene expression changes were observed at 2 weeks of diabetes, and only two statistically significant expression changes were observed at 1 month (Supplementary Figure  S1 ). This analysis, combined with the functional data above, provides consistent evidence that the changes in gene expression coincide with manifestation of functional changes at 3 months, and do not occur at 1 month or 2 weeks. Indeed, 3 months of diabetes in the STZ rats impairs the functions of glial, microglial, vascular and neuronal cells and their interconnections (reviewed by Antonetti et al.
32
), and results in decreased pro-survival insulin receptor signaling to a greater degree than after 1 month. 28 Four additional animal experiments (Experiments 4-7) at the 3-month time point were also generated for use in the classification analysis below.
Step 4: Determine gene panel with highest classification accuracy The fourth step of the process was to identify the panel of genes that would best serve as a measure of disease and effectiveness of treatment by testing the biomarker panel on independent samples (Step 4, Figure 1 ). First, the 25 genes confirmed in Step 3 were used to classify, by a SVM algorithm with a polynomial kernel function and no scaling factor, the animals in Experiments 4-7 (Test set) using the data from Experiments 1-3 as a Training set. These 25 genes were highly accurate (96%) in classifying the de-identified samples from Experiments 4-7 (Figure 3a) . Although animal identities are never unknown in the preclinical setting, this process allows a mathematical determination of how well the biomarkers can differentiate control from disease at the level of individual animals. 24 Statistically significant expression differences can exist between population means for individual genes, but because the goal of the biomarker usage in preclinical drug development is to identify effective Table 3 Progression of genes through biomarker panel development process
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Tnfrsf12a Vcam1 Znf219 treatment at the individual animal level, a classification analysis method combines the individual gene measurements into a single determination of efficacy.
Next, an analysis was conducted to determine if a smaller panel of genes could work as effectively in segregating control and diabetic animals. Two gene selection approaches (Fisher's exact test and the Golub method 33 ) were used in a cross-validation approach on the training set data (Experiments 1-3) , and both returned a result that 14 genes was the minimal panel size that could return an equivalent result to the original 25 genes (Figure 3b ). The two gene selection methods returned highly similar sets of genes with 12 genes in common between the two sets, and the only differences being the inclusion of Mct1 and Tnfrsf12a by the Fisher's exact method and Hspb1 and Chi3l1 by the Golub method.
The classification accuracy of the two 14 gene sets were then analyzed using Experiments 1-3 as a Training set for the SVM algorithm and Experiments 4-7 as the Test set. The Golub method gene set returned the highest accuracy (97%, Figure 3c ), whereas the Fisher's exact gene set achieved 94% accuracy (data not shown). The 14 gene Golub method gene panel produced a higher accuracy classification than the 25 gene panel, showing that this 14 gene panel can be used with optimal classification accuracy. Additional analyses in which the Training and Test sets were reversed returned equivalent results indicating a reproducible model. As well, a Gaussian kernel function for the SVM algorithm and inclusion of scaling factors were tested but returned inferior results to the polynomial kernel function.
Step 5: Response of gene expression to a known therapeutic agent The fifth step of the process is a positive control experiment that determines whether a proven pharmacotherapeutic agent (insulin) could alter the response of the biomarker panel. This step may not be possible for those diseases that have no known effective therapy. For many conditions, including DR, existing drugs have only partial efficacy. These can be used as a test for the biomarker panel and its ability to differentiate effective from ineffective treatment.
Gene expression changes were examined in rats after 1, 2 and 3 months of diabetes with and without treatment by subcutaneous slow-release insulin implants for the latter half of the duration of diabetes. In the 3-month diabetic animals, 1 1 2 months of insulin treatment reduced or eliminated diabetes-induced expression changes in the 14 gene biomarker panel (Figure 4a ). These partial responses are typical of subcutaneous insulin delivery, which does not provide physiological responses to the systemic nutrient overload. At the individual animal level, the responses had some heterogeneity as shown in the heat-map representation where each column represents an individual animal (Figure 4b) . Likewise, subcutaneously administered insulin effectively reduces the risk of complications but does not entirely prevent DR in humans 11 or in animals. 30 One month and 2 months of diabetes with insulin treatment for 2 weeks and 1 month, respectively, showed similar results, though the expression changes at these time points with diabetes are limited (Supplementary Figure S2) .
As a demonstration of how a biomarker panel and the classification approach would be used in drug efficacy testing, the animals in Experiment 8 (3-month time point) were classified using the 14 gene Golub method panel and Experiments 1-7 as Training set data. Diabetic animals treated with insulin were classified as control 83% of the time whereas 17% were classified as diabetic (Figure 4c ). Insulin treatment reversed the diabetes disease signature, as expected with an effective therapeutic agent, showing both the classification ability of the biomarker panel and its potential use as an indicator of pharmacoefficacy. For completeness, the classification accuracy of the 25 genes consistently regulated in Experiments 1-3 (Figure 3b ) and the 14 gene Fisher's exact method set were also tested in the insulin experiment and both were found to misclassify one of the untreated diabetic animals and only classify 66% of the insulin-treated diabetic animals as control, showing that the 14 gene Golub method panel has superior classification ability.
The lack of total reversion of all diabetic animals to a control classification was expected because insulin treatment does not entirely prevent DR in humans 11 or in animals. 30 Indeed, understanding the disease components that fail to respond to treatment may be important for therapeutic design optimization.
To visualize the totality of the results from all of the experiments, we created a gene expression heat map with condition clustering to show the relationship of each different animal experiments and treatment groups using the 14 gene panel ( Figure 5 ). All diabetic groups clustered together, as did all control groups, with the insulin-treated group clustering at a midpoint between the two. The final biomarker panel (the 14 genes in the heat map) contains both upregulated and downregulated transcripts and, as expected, is partially normalized by insulin treatment.
For comparison, a heat map of the 1-month time point data was also generated (Supplementary Figure S3) . Gene expression changes at the 1-month time point are limited in number and magnitude, though the animals are hyperglycemic to similar extents at both 1 and 3 months of diabetes (Table 1) . Gene expression changes predominantly occur at 3 months of diabetes when tissue dysfunction has developed, so these changes result from sustained hyperglycemia and/or insulin deficiency and retinal dysfunction, and not acute hyperglycemia alone. Figure 3 Classification ability of the biomarker panel. The smallest panel with the highest classification accuracy was achieved through several steps. First, qPCR data from the 25 genes that were regulated in a statistically significant manner in Experiments 1-3 were used to test the ability of the biomarker panel to classify de-identified samples correctly as control, or diabetic. Using a support vector machine (SVM) algorithm and a Training set composed of data from animal Experiments 1-3, we classified individual animals in Experiments 4-7, the Test set. The biomarker panel performed with 96% accuracy in the 69 samples tested (a). Next, to determine the smallest number of genes with the highest classification accuracy, two gene selection methods were used (Fisher's exact test and Golub method). Both methods showed that the number of genes could be reduced to the same 14 genes without any increase in misclassification rate within the Training set (b). The 14 gene panel was then used in the support vector machine (SVM) algorithm on the independent Test set data and returned the same accuracy as the larger 25 gene (c).
Fisher Exact Golub
To meet criteria for a 'probable valid biomarker', we addressed the extent to which qPCR technical sources of variance contribute to variation among animal groups. 24 Using RNA from rats in Set 1, we processed two parallel RNA aliquots for cDNA synthesis and qPCR analysis. Minimal variation (3-10%) was observed between technical replicates, suggesting that the differences between replicate sets of rats are due to inherent biological differences, not due to variability in the qPCR assay itself (Supplementary Figure S4 ).
Discussion
In this report, we define a five-step process by which a gene expression biomarker panel for preclinical drug development can be validated and provide a case study of this validation process. Although the data provide an example of a gene expression panel for DR, this linear development process is relevant for other diseases. In fact, the process is also applicable to development of protein-and metabolite-based biomarkers, and not solely to gene expression or DR.
Substantial attention has been paid to the potential use of gene expression biomarkers in preclinical drug development, 1,2 but few reports describe the validation process for such biomarkers. [8] [9] [10] Molecular biomarkers offer the potential to conduct initial preclinical drug development more quickly and efficiently. Traditionally, disease-specific physiological or behavioral tests are used to measure therapeutic efficacy but these assays are often difficult to perform and have limited gain, which impedes identification of treatments with partial efficacy. For example, in DR, measures of 
mean±s.e.m., Experiment 8, n ¼ 6-9 per group. The individual animals showed differential levels of gene expression changes relative to controls (b). Using the same Training set data and SVM algorithm as before, we performed the classification analysis of the control, diabetic and diabetic þ insulin groups (c). 83% of the diabetic animals treated with therapeutic were classified as control and 17% as diabetic, as expected for a treatment which, while efficacious, does not prevent all incidences of DR.
cell death and retinal vascular permeability are induced by less than 75% with disease in our model system (Table 2) . 19 Molecular biomarkers with larger magnitude changes and/or panels of genes may have greater power in determining efficacy, especially in initial screens of many different compounds, doses, or delivery methods. In addition, a biomarker panel containing multiple genes representing a variety of pathways, cell types and responses permits a broader readout for pathological change or therapeutic intervention. A rational and consistent process is needed for the determination of biomarker panels, and to this end we propose and show the use of a biomarker development process.
Each step of the development process serves to address a specific aspect of the biomarker panel and its use. Determination of the time course of tissue or organism pathology allows for biomarker (for example, gene expression) results to be tied to pathophysiology. Biomarker discovery by a broad screening approach, in this case gene expression analysis through microarrays, generated initial targets for biomarker development. Testing the reproducibility of the gene expression changes across multiple, independent animal experiments focused the biomarker panel on the most robust and consistently regulated transcripts. Next, the panel was refined to determine the minimal set of genes that could accurately classify individual animals in independent experiments from those used to create the model. The gene expression biomarker panel response to an established therapeutic agent was then used to show that the classification approach could identify an effective therapy and can therefore be used to gauge pharmacoefficacy of experimental compounds. Importantly, for implementation of biomarker panels in the drug development process, the data used in building the biomarker panel model can continue to be used in drug testing. For example, in this case study, Experiments 1-7 were used as the Training set data for testing insulin efficacy. The classification approach has the added benefit of integrating gene expression across multiple genes into a single value. Maximally effective treatments will result in control classifications, whereas partially effective treatments will produce a control classification in some but not all animals. Ineffective treatments will not change the classification of disease group animals. Future drug development efforts will use the same biomarker panel and algorithm to ensure that the disease model is consistent and to enable rapid assessment of the potential efficacy of different compounds, doses, formulations and routes of administration.
The primary aim of this study was to show a procedure for the development of preclinical biomarkers; nevertheless, the results also provide new insights into DR pathophysiology. Specific potential roles for individual genes are described in the Supplementary Discussion. However, showing causality for biomarkers in disease processes is not the aim of biomarker development. Rather, we show that these changes coincide with broad manifestations of altered retinal function in the form of increased retinal vascular permeability and caspase-3 activity. Although not all genes passed the biomarker criteria, this does not obviate their potential importance in the etiology of DR, and means only they are not suitable components of the biomarker panel according to the accepted definition, at least for the stage of DR examined in this study. Furthermore, we show that the individual gene expression changes, and thereby the biomarker panel as a whole, is reversed or ameliorated by insulin, the definitive pharmacotherapeutic agent for insulin-deficient diabetes and DR. Intensive insulin therapy has been shown clinically 11, 34 to delay DR development and progression, and along with lifestyle modifications has become the standard of care for preventing or delaying DR progression. 12 The efficacy of insulin treatment in the STZ rat model has been established for many years. In the STZ rat model, insulin treatment has been previously shown to be effective in traditional endpoint analyses of retinal vascular defects 35, 36 and retinal neuronal apoptosis 30, 37, 38 with diabetes. On the basis of these findings, insulin was used as a positive pharmacotherapeutic control to show the ability of the biomarker panel to respond to an effective therapy. In the testing of new, experimental compounds, doses and delivery methods, positive biomarker results will justify further investigation by more expensive and time-consuming traditional endpoint analyses.
In this case study, mRNA was chosen as the molecular biomarker to be measured over alternatives such as proteins or metabolites. The utility of mRNA expression levels as biomarkers has been shown both preclinically 8 and clinically. [39] [40] [41] [42] mRNA biomarkers offer the practical utility of high-throughput, specific measurements with high sensitivity and readily available research reagents, whereas requiring minimal starting sample/tissue amounts. As proteomic technology continues to mature, more preclinical biomarker development will focus on protein biomarkers. We have applied discovery proteomic approaches to this same disease model. 27 Even with new tools such as Luminex and multiple-reaction-monitoring mass spectrometry, the development of high-throughput protein biomarker panels requires extensive technique development of antibodies or mass spectrometry peptide standards. RNA assays require minimal development before usage.
By showing that these gene expression changes (1) are highly reproducible, (2) coincide with changes in retinal dysfunction, (3) are accurate classifiers of disease state and (4) are reversed by the definitive therapeutic agent, this development process fully complies with the NIH biomarker definition. 4 This biomarker panel can be considered as a 'probable valid biomarker'. 24 The resultant biomarker panel provides a tool to monitor a preclinical DR model and evaluate the efficacy of potential pharmacotherapeutic interventions. This biomarker panel can be used as an initial screen of pharmacoefficacy in compound, dosing, delivery and formulation studies. We continue to confirm and validate further retinal gene and protein expression changes to gain deeper insight into DR disease processes. 29 In addition, this biomarker panel provides further support of the hypothesis that DR is a feed forward cycle of nutrient overload leading to chronic inflammation, neurodegeneration and compromised blood-retinal barrier function. 32 Future studies will use this biomarker panel in preclinical research of potential therapeutics to monitor disease models and gauge pharmacoefficacy, with the expectation that effective treatments will alter the DR gene expression biomarker panel signature.
The preclinical biomarker process proposed is rigorous in that the biomarker panel must pass multiple stages of development. These detailed experiments provide a basis for rational decision-making in the drug development process. Although there is great interest in using biomarkers during preclinical drug development, to the best of our knowledge this is the first report to define a specific, step-wise validation process for preclinical biomarkers. The biomarker development process is not specific to DR and can be readily transferred to other complex diseases with use of diseasespecific experimental models and disease-appropriate functional measurements.
